Google
AVLN — AVALYN PHARMA INC. COMMON STOCK (Healthcare >> Biotechnology)
AVLN FAQ
What is AVLN's ROE?
AVALYN PHARMA INC. COMMON STOCK reports a Return on Equity (ROE) of 0.00%.
What is AVLN's dividend yield?
AVALYN PHARMA INC. COMMON STOCK offers a dividend yield of 0.00%.
What is AVLN's Deepscope Quality Score?
Deepscope rates AVLN's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AVLN?
Deepscope's AI Timing Score for AVLN is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AVLN belong to?
AVALYN PHARMA INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 27.06
Price
0.07
(0.26%)
Day Change
|
|
|---|
AVLN, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 79 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 27.06 |
| PBV / Sector |
5.01 / 4.63
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
7.29 M
|
| Average 1W Daily Value |
5.48 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:38 |
| Symbol | AVLN |
| Name | AVALYN PHARMA INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 44.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,169.84 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 105 W First Street, Boston, MA, United States, 02127
Phone: (206) 707-0340
Website: https://www.avalynpharma.com
Sector: Healthcare >> Biotechnology
Description: Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
